|
1
|
Poon D, Anderson BO, Chen LT, et al:
Management of hepatocellular carcinoma in Asia: consensus statement
from the Asian Oncology Summit 2009. Lancet Oncol. 10:1111–1118.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cammà C, Schepis F, Orlando A, Albanese M,
Shahied L, Trevisani F, Andreone P, Craxì A and Cottone M:
Transarterial chemoembolization for unresectable hepatocellular
carcinoma: meta-analysis of randomized controlled trials.
Radiology. 224:47–54. 2002.PubMed/NCBI
|
|
3
|
Lin HL, Lui WY, Liu TY and Chi CW:
Reversal of Taxol resistance in hepatoma by cyclosporine A:
involvement of the PI-3 kinase-AKT 1 pathway. Br J Cancer.
88:973–980. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang X, Lin X, Zhong X, et al:
Double-negative feedback loop between reprogramming factor LIN28
and microRNA let-7 regulates aldehyde dehydrogenase
1-positive cancer stem cells. Cancer Res. 70:9463–9472. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lv K1, Liu L, Wang L, et al: Lin28
mediates paclitaxel resistance by modulating p21, Rb and Let-7a
miRNA in breast cancer cells. PLoS One. 7:e 400082012.PubMed/NCBI
|
|
6
|
Teng RY, Zhou JC, Jiang ZN, Xu CY, Li ZD,
Wang QC, Xu CP, Guo JF, Shen JG and Wang LB: The relationship
between Lin28 and the chemotherapy response of gastric cancer. Onco
Targets Ther. 6:1341–1345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Viswanathan SR, Powers JT, Einhorn W,
Hoshida Y, Ng TL, Toffanin S, et al: Lin28 promotes transformation
and is associated with advanced human malignancies. Nat Genet.
41:843–848. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Viswanathan SR, Daley GQ and Gregory RI:
Selective blockade of microRNA processing by Lin28. Science.
320:97–100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heo I, Joo C, Cho J, Ha M, Han J and Kim
VN: Lin28 mediates the terminal uridylation of let-7 precursor
microRNA. Mol Cell. 32:276–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shimizu S, Takehara T, Hikita H, et al:
The let-7 family of microRNAs inhibits Bcl-xL expression and
potentiates sorafenib-induced apoptosis in human hepatocellular
carcinoma. J Hepatol. 52:698–704. 2010.
|
|
11
|
Tian N, Li X, Luo Y, Han Z, Li Z and Fan
C: Curcumin regulates the metabolism of low density lipoproteins by
improving the C-to-U RNA editing efficiency of apolipoprotein B in
primary rat hepatocytes. Mol Med Rep. 9:132–136. 2014.PubMed/NCBI
|
|
12
|
Cavalieri EL, Stack DE, Devanesan PD, et
al: Molecular origin of cancer: catechol estrogen-3,4-quinones as
endogenous tumor initiators. Proc Natl Acad Sci USA.
94:10937–10942. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kool M1, de Haas M, Scheffer GL, Scheper
RJ, van Eijk MJ, Juijn JA, Baas F and Borst P: Analysis of
expression of cMOAT (MRP2), MRP3, MRP4, and
MRP5, homologues of the multidrug resistance-associated
protein gene (MRP1), in human cancer cell lines. Cancer Res.
57:3537–3547. 1997.PubMed/NCBI
|
|
14
|
Lin HL, Liu TY, Lui WY and Chi CW:
Up-regulation of multidrug resistance transporter expression by
berberine in human and murine hepatoma cells. Cancer. 85:1937–1942.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Zhao J, Zhang W, Liu G, Yin D, Li
J, Zhang S and Li H: Establishment of paclitaxel-resistant cell
line and the underlying mechanism on drug resistance. Int J Cynecol
Cancer. 22:1450–1456. 2012.PubMed/NCBI
|
|
16
|
Işeri OD, Kars MD, Eroglu S and Gündüz U:
Drug resistant MCF-7 cell lines also developed cross-resistance to
structurally unrelated anticancer agents. UHOD. 19:1–8. 2009.
|
|
17
|
Andersen MH, Becker JC and Straten Pt:
Regulators of apoptosis: suitable targets for immune therapy of
cancer. Nat Rev Drug Discov. 4:399–409. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu K, Qian T, Tang L, Wang J, Yang H and
Ren J: Decreased expression of microRNA let-7i and its association
with chemotherapeutic response in human gastric cancer. World J
Surg Oncol. 10:2252012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takehara T, Liu X, Fujimoto J, Friedman SL
and Takahashi H: Expression and role of Bcl-xL in human
hepatocellular carcinomas. Hepatology. 34:55–61. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lessene G, Czabotar PE and Colman PM:
BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov.
7:989–1000. 2008. View
Article : Google Scholar : PubMed/NCBI
|
